XJZY(SZ:002332)2021-08-24 16:00Financial Performance - The company's operating revenue for the first half of 2021 was CNY 2,143,203,846.80, representing a 21.03% increase compared to CNY 1,770,808,591.63 in the same period last year[29]. - The net profit attributable to shareholders of the listed company reached CNY 274,040,318.92, up 33.47% from CNY 205,317,915.18 in the previous year[29]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 270,554,642.01, reflecting a 37.11% increase from CNY 197,328,956.79 year-on-year[29]. - The basic earnings per share increased to CNY 0.28, a rise of 27.27% compared to CNY 0.22 in the same period last year[29]. - The total assets at the end of the reporting period were CNY 6,887,522,958.74, showing a 0.72% increase from CNY 6,838,231,066.49 at the end of the previous year[29]. - The net assets attributable to shareholders of the listed company increased by 2.35% to CNY 4,549,287,414.08 from CNY 4,444,931,882.40 at the end of the previous year[29]. - The net cash flow from operating activities was CNY 234,107,076.76, which is a decrease of 4.14% compared to CNY 244,208,628.76 in the same period last year[29]. - The weighted average return on net assets was 6.06%, down from 6.81% in the previous year, indicating a decrease of 0.75%[29]. Revenue Breakdown - Sales revenue from formulations was 1.162 billion yuan, a 31% increase, with self-operated product sales reaching 1.134 billion yuan, up 38%[40]. - The sales revenue of raw materials and intermediates was 964 million yuan, a 9.5% increase, with self-operated raw material sales at 595 million yuan, up 16%[40]. - Domestic sales accounted for ¥1,527,052,896.59, which is 71.25% of total revenue, showing a growth of 29.09% compared to the previous year[69]. - The revenue from anesthetics and muscle relaxants surged by 68.86% to ¥393,975,393.22, contributing 18.38% to total revenue[69]. Research and Development - Research and development expenses increased by 30.48% to CNY 99,242,121.29, up from CNY 76,058,999.29 in the previous year[66]. - The company is actively advancing product research and development, with several new drug applications and consistency evaluations in progress, including Dexamethasone sodium phosphate injection[51]. - The company has successfully passed consistency evaluations for several products, including Finasteride tablets and Mifepristone tablets, enhancing its product portfolio[51]. - The company has submitted applications for 22 consistency evaluation products, with 8 submitted and 4 passed, and 18 new generic products, with 5 submitted[54]. Market Position and Strategy - The company focuses on the steroid drug sector, emphasizing the integration of raw materials and formulations to enhance competitiveness[45]. - The company is actively expanding its international market presence, with steady progress in developing raw material customers[45]. - The company is positioned in a stable competitive landscape within the steroid hormone industry, maintaining a strong market share in the first tier of the industry[49]. - The steroid drug industry in China accounts for approximately one-third of the global production of steroid raw materials, indicating a significant production capacity[47]. Risks and Challenges - The company has identified several risks including industry policy changes, drug price reduction risks, and R&D risks, which are detailed in the management discussion section[6]. - The company faces risks from industry policy changes and potential drug price reductions due to stricter regulations and reforms in the healthcare system[97]. - Quality control risks are heightened due to new regulations and standards impacting the entire lifecycle of drug development and production[98]. - R&D risks are present due to high investment and long cycles associated with new drug development, necessitating a focus on core therapeutic areas[98]. - Environmental risks are increasing due to stricter pollution control regulations, prompting the company to enhance its environmental protection measures[99]. Environmental Responsibility - The company reported a total COD discharge of 1.01 tons and ammonia nitrogen discharge of 0.27 tons from its Jiangnan plant, adhering to environmental standards[110]. - The company has a pollution prevention facility in operation, ensuring compliance with environmental regulations[113]. - The company achieved a stable operation rate of over 99% for its environmental protection facilities during the reporting period[114]. - The company has established a complete internal control system and an investor interaction platform to ensure fair treatment of all shareholders[120]. Shareholder Information - The total number of shareholders at the end of the reporting period was 35,247, with a significant shareholder, Xianju County State-owned Assets Investment Group Co., Ltd., holding 21.55% of shares, totaling 213,221,808 shares[190]. - The total number of shares is 989,204,866, with 97.30% being unrestricted shares[182]. - The company has a total of 4,379,562 shares subscribed by Huatai Asset Management Co., Ltd. and 4,014,598 shares by China Merchants Fund Management Co., Ltd., both of which have also completed their lock-up commitments[135][138]. - The report indicates that the company has not experienced any significant changes in shareholder structure during the reporting period[190].